In vivo effects of chronic treatment with [Met5]-enkephalin on hematological values and natural killer cell activity in athymic mice

Life Sciences

Volumn 66, Issue 9, 2000, Pages 829-834

  Zalys, Ramunas ^a   Zagon, Ian S ^a   Bonneau, Robert H ^a   Lang, C Max ^a   McLaughlin, Patricia J ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Lithuanian Veterinary Academy   (Lithuania)

Author keywords

Cancer; Enkephalin; Immunology; Natural killer cell; Opioid antagonist

Indexed keywords

METENKEPHALIN; NALTREXONE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; IMMUNOLOGY; IN VIVO STUDY; KILLER CELL; LEUKOCYTE ACTIVATION; LYMPHOCYTE TRANSFORMATION; MOUSE; NONHUMAN; RECEPTOR BLOCKING; TUMOR XENOGRAFT;

ANIMALS; BLOOD CELL COUNT; BODY WEIGHT; ENKEPHALIN, METHIONINE; KILLER CELLS, NATURAL; LEUKOCYTE COUNT; MALE; MICE; MICE, NUDE; NALTREXONE; NARCOTIC ANTAGONISTS; ORGAN SIZE; SPLEEN;

ANIMALIA;

EID: 0034695434     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(99)00655-4     Document Type: Article

References (28)

1. D.J.J. Carr, Proc. Soc. Exp. Biol. Med. 198 710-720 (1991).
2. G.B. Stephano, B. Scharrer, E.M. Smith, T.K. Hughes, H.I. Belfinger, A.R. Hartman, G.L. Fricchione, Y. Liu and M.H. Makman, Crit. Rev. Immunol. 16 109-144 (1996).
3. J.J. Madden, W.L. Whaley and D. Ketelsen, J. Neuroimmunol. 83 57-62 (1996).
4. D.J.J. Carr, T.J. Rogers and R.J. Weber, Proc. Soc. Exp. Biol. & Med. 213 248-457 (1996).
5. J. Wybran, T. Appelboom, J.-P. Famaey and A. Govaerts, J. Immunol. 123 1068-1070 (1979).
6. P.M. Mathews, C.J. Froelich, W.L. Sibbitt and A.D. Bankhurst, J. Immunol. 130 1658-1662 (1983).
7. N.P. Plotndcoff, G.C. Miller, N. Nimeh, R.E. Faith, A.J. Murgo and J. Wybran, Ann. NY Acad. Sci. 496 608-619, 1987.
8. Y. Kikuchi, T. Kita and I. Nagata, Cancer Immunol., Immunother. 30 374-376 (1990).
9. N.P. Plotnikoff, A.J. Murgo and R.E. Faith, Clin. Immunol. Immunopharmacol. 32 52-56 (1984).
10. L. Perez and D.T. Lysle, J. Neuroimmunol. 79 101-112 (1997).
11. N.P. Plotnikoff, A.J. Murgo, G.C. Miller, C.N. Corder and R.E. Faith, Fed. Proc. 44: 118-122 (1985).
12. J. Wybran, L. Schandene, J-P. Van Vooren, G. Vandermoten, D. Latinne, J. Sonnet, M. de Bruyere, H. Taelman and N.P. Plotnikoff, Ann. N. Y. Acad. Sci. 496 108-114 (1987).
13. N.P. Plotnikoff and G.C. Miller, Int. J. Immunopharmacol. 5 437-441 (1983)
14. A.J. Murgo, JNCI 75 341-344 (1985).
15. I.S. Zagon, S.D. Hytrek, C.M. Lang, J.P. Smith, T.J. McGarrity, Y. Wu and P.J. McLaughlin, Amer. J. Physiol. 271 R780-R786 (1996).
16. I.S. Zagon, S.D. Hytrek, J.P. Smith and P.J. McLaughlin, Cancer Lett. 112 167-175 (1997).
17. P.J. McLaughlin and I.S. Zagon, Life Sci. 41 1465-1472 (1987).
18. th ed.,. Lea & Febriger, Philadelphia, 1986.
19. K.T. Brunner, J. Mauel, J.C. Cerottini and B. Chapuis, Immunol. 14 181-196 (1968).
20. R. Kiessling, G. Petranyi, G. Klein and H Wigzel, Int. J. Cancer 15 933-940 (1975).
21. P.K. Peterson, B. Sharp, G. Gekker, C. Brummitt and W.F. Keane, J. Clin. Invest. 80 824-831 (1987).
22. R.E. Faith, H.J. Liang, A.J. Murgo and N.P. Plotnikoff, Clin. Immunol. Immunopathol. 31 412-418 (1984).
23. F. Zhong, X.Y. Li and S.L. Yang, Acta Pharmacol. Sinica. 17 182-185 (1996).
24. J. Kowalski, Eur. J. Pharmacol. 347 95-99 (1998).
25. D.J.J. Carr and J.E. Blalock, Psychoneuroendocrinol. 16 407-415 (1991).
26. T. Marotti., J. Gabrilovac, S. Rabatic, L. Smejkal-Jagar, B. Rocic and H. Haberstock, Pharmacol. Biochem. & Behavior. 54 277-84 (1996).
27. I.S. Zagon, J.P. Smith and P.J. McLaughlin, Int. J. Oncol. 14 577-584 (1999).
28. P.J. McLaughlin, R.J. Levin and I.S. Zagon, Int. J. Oncol. 14 991-998 (1999).